NCT06315426 - A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR). | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

March 24, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

October 31, 2025

Conditions

Allergic Rhinitis

Interventions

BIOLOGICAL

GR1802 injection

Recombinant fully human anti-IL4Rα monoclonal antibody drug.

BIOLOGICAL

Placebo

Trial Locations (15)

250000

Qilu Hospital of Shandong University, Jinan

Shandong Second Provincial General Hospital, Jinan

252000

Liaocheng People's Hospital, Liaocheng

430000

The Central Hospital of Wuhan, Wuhan

Wuhan Union Hospital of China, Wuhan

434000

Jingzhou Central Hospital, Jingzhou

450000

Zhengzhou Central Hospital, Zhengzhou

610000

Chengdu Second People's Hospital, Chengdu

710000

Xi'an Daxing Hospital, Xi’an

065000

Hebei Petro China Central Hospital, Langfang

054800

Central Hospital of Qinghe County, Xingtai

046000

Heping Hospital Affiliated to Changzhi Medical College, Changzhi

030000

First Hospital of Shanxi Medical University, Taiyuan

Shanxi Bethune Hospital, Taiyuan

044000

Yuncheng Central Hospital, Yuncheng

All Listed Sponsors

lead

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

INDUSTRY